News

Novel FGFR2 Inhibitor Shows Promise in Patients With Cholangiocarcinoma and an FGFR2-Fusion or Rearrangement

10/20/2022

According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.

According to a phase 1/2 study,...

10/20/2022

Oncology

News

FDA Approves Futibatinib for Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements

10/03/2022

Allison Casey ;

On September 30, 2022, the US FDA granted accelerated approval to futibatinib, 20 mg orally daily, for patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.

On September 30, 2022, the US...

10/03/2022

Oncology

News

Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients With Intrahepatic Cholangiocarcinoma and EGFR2 Aberrations

09/30/2022

Allison Casey ;

Results from a phase 2 trial showed that derazantinib as a second-line treatment resulted in meaningful clinical benefit for patients with intrahepatic cholangiocarcinoma and EGFR2 aberrations.

Results from a phase 2 trial...

09/30/2022

Oncology

News

Nivolumab Plus Gemcitabine and S-1 Demonstrates Potential in Advanced Biliary Tract Cancer

09/28/2022

Allison Casey ;

Results from a phase 2 trial show that modified gemcitabine and S-1 plus nivolumab is a safe and promising regimen for patients with advanced biliary tract cancer, with impaired function of chromatin remodeling genes as a potential surrogate...

Results from a phase 2 trial...

09/28/2022

Oncology

News

Nivolumab Added to Chemotherapy or Ipilimumab Offers No Survival Benefit in Advanced Biliary Tract Cancer

08/31/2022

Allison Casey ;

Findings from a phase 2 trial suggest adding nivolumab to either chemotherapy or ipilimumab provides no PFS benefit in the first-line treatment of patients with advanced biliary tract cancer.

Findings from a phase 2 trial...

08/31/2022

Oncology

News

Second-Line Sintilimab Plus Lenvantinib Demonstrates Efficacy, Safety in Intrahepatic Cholangiocarcinoma

08/31/2022

Allison Casey ;

In the second-line treatment setting, sintilimab combined with lenvatinib demonstrated promising efficacy and tolerability among patients with advanced intrahepatic cholangiocarcinoma, according to a multicenter observational study.

In the second-line treatment...

08/31/2022

Oncology

News

Immune Checkpoint Inhibitor Monotherapy Demonstrates Antitumor Activity in Advanced Biliary Tract Cancer

08/10/2022

Allison Casey ;

Study findings show immune checkpoint inhibitors are well-tolerated and demonstrate antitumor activity in patients with biliary tract cancers, especially those with high tumor mutational burden.

Study findings show immune...

08/10/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Conference Coverage

Durvalumab Added to Gemcitabine and Cisplatin Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

06/30/2022

Allison Casey ;

First-line treatment with durvalumab plus gemcitabine and cisplatin was associated with improved efficacy outcomes among patients with biliary tract cancer irrespective of the primary tumor location, according to results from the phase 3...

First-line treatment with...

06/30/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology